CD27 is a member of the tumor necrosis factor (TNF) receptor superfamily, which includes the T cell co-stimulatory receptors OX40, 4-1BB and herpesvirus entry mediator (HVEM). CD27 is expressed on various types of T cells, B cells and a subset of natural killer cells. It activates NF-κB and MAPK/JNK signaling upon interaction with its TNF-like ligand, CD70, which is expressed by numerous tumor cells. Adaptor proteins TRAF2 and TRAF5 can also stimulate CD27 signaling. Activation of CD27 leads to lymphoid proliferation, differentiation, apoptosis, and the induction of long-term memory. The CD27/CD70 pathway is a key target for the development of treatments for cancer and inflammatory diseases.
|Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NF-kB response elements with constitutive expression of human CD27 (also known as Tumor Necrosis Factor Receptor Superfamily Member 7, TNFRSF7, and T14, Genbank Accession #BC012160)|
|Stability:||32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)|
|Synonym(s):||Tumor Necrosis Factor Receptor Superfamily Member 7, TNFRSF7, T14, cd27 cell line, cd-27, nfkb, nf-kb|
|Freeze Medium:||90% FBS+10% DMSO|
|Culture Medium:||RPMI-1640+10%FBS+800ug/ml hygromycin+1ug/ml puromycin|
•Screen for agonists or antagonists of CD27-CD70 signaling in a physiologically relevant cellular context
•Characterize T cell-mediated immune responses of CD27 and its interaction with CD70
|IV. Description of Host Cell Line|
|Organism:||Homo sapiens, human|
|Disease:||Childhood T acute lymphoblastic leukemia|
|Ⅴ. Representative Data|
Figure 1. Recombinant Jurkat stably expressing human CD27-NFκB.
Figure 2. Detect Luciferase assay by Promega Bright-Glo Luciferase Assay System. Jurkat-CD27-NFκB-Luciferase Reporter cells were stimulated by CD70/CHO cells, the S/B was 26.5-fold.